Psychological correlates of antibody response to mRNA SARS-CoV-2 vaccination: A prospective observational cohort study

IF 8.8 2区医学 Q1 IMMUNOLOGY

Brain, Behavior, and Immunity Pub Date : 2025-03-11 DOI:10.1016/j.bbi.2025.03.011

Kieran Ayling , Hannah Jackson , Ru Jia , Simon Royal , Lucy Fairclough , Kavita Vedhara

{"title":"Psychological correlates of antibody response to mRNA SARS-CoV-2 vaccination: A prospective observational cohort study","authors":"Kieran Ayling , Hannah Jackson , Ru Jia , Simon Royal , Lucy Fairclough , Kavita Vedhara","doi":"10.1016/j.bbi.2025.03.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Vaccines fundamentally changed the course of the COVID-19 pandemic, saving > 14 million lives within a year. However, vaccine-conferred protection showed inter-individual variability, with many identified correlates of protection (e.g., age) not amenable to change. This prospective observational cohort study examined whether modifiable psychological factors (depressive symptoms, anxiety, perceived stress and positive mood), which predict antibody responses to other vaccines, also influenced the effectiveness of COVID-19 vaccines. We focussed on novel mRNA vaccines as these conferred greater clinical protection and psychological correlates have not been investigated in these vaccines previously.</div></div><div><h3>Methods</h3><div>One-hundred and eighty-four adults attending a mass-vaccination centre in the UK received a two-dose BNT162b2 mRNA SARS-CoV-2 vaccine course, completed validated psychological measures, and provided blood samples prior to vaccination and 4 weeks following the second vaccine dose.</div></div><div><h3>Results</h3><div>In separate linear regression models controlling for pre-vaccination antibody levels, demographic and clinical factors, higher levels of depressive symptoms (β = -0.15 [95 % CI: −0.30, −0.01], <em>p</em> = 0.041, partial <em>f</em><sup>2</sup> = 0.009) and lower levels of positive mood (β = 0.16 [95 % CI: 0.01, 0.30], <em>p</em> = 0.036, partial <em>f</em><sup>2</sup> = 0.011) were significantly associated with lower SARS-CoV-2 spike-specific antibody levels following vaccination. No significant relationships were observed between measures of anxiety or perceived stress and antibody responses.</div></div><div><h3>Conclusions</h3><div>Lower levels of depressive symptoms and greater positive mood were associated with larger antibody responses following mRNA SARS-CoV-2 vaccination in a community sample attending for their first course of COVID-19 vaccinations. As both are amenable to change, they could offer mechanisms for enhancing vaccine effectiveness particularly among populations at greater risk of vaccine failure.</div></div>","PeriodicalId":9199,"journal":{"name":"Brain, Behavior, and Immunity","volume":"127 ","pages":"Pages 103-109"},"PeriodicalIF":8.8000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain, Behavior, and Immunity","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0889159125000972","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Vaccines fundamentally changed the course of the COVID-19 pandemic, saving > 14 million lives within a year. However, vaccine-conferred protection showed inter-individual variability, with many identified correlates of protection (e.g., age) not amenable to change. This prospective observational cohort study examined whether modifiable psychological factors (depressive symptoms, anxiety, perceived stress and positive mood), which predict antibody responses to other vaccines, also influenced the effectiveness of COVID-19 vaccines. We focussed on novel mRNA vaccines as these conferred greater clinical protection and psychological correlates have not been investigated in these vaccines previously.

Methods

One-hundred and eighty-four adults attending a mass-vaccination centre in the UK received a two-dose BNT162b2 mRNA SARS-CoV-2 vaccine course, completed validated psychological measures, and provided blood samples prior to vaccination and 4 weeks following the second vaccine dose.

Results

In separate linear regression models controlling for pre-vaccination antibody levels, demographic and clinical factors, higher levels of depressive symptoms (β = -0.15 [95 % CI: −0.30, −0.01], p = 0.041, partial f² = 0.009) and lower levels of positive mood (β = 0.16 [95 % CI: 0.01, 0.30], p = 0.036, partial f² = 0.011) were significantly associated with lower SARS-CoV-2 spike-specific antibody levels following vaccination. No significant relationships were observed between measures of anxiety or perceived stress and antibody responses.

Conclusions

Lower levels of depressive symptoms and greater positive mood were associated with larger antibody responses following mRNA SARS-CoV-2 vaccination in a community sample attending for their first course of COVID-19 vaccinations. As both are amenable to change, they could offer mechanisms for enhancing vaccine effectiveness particularly among populations at greater risk of vaccine failure.

查看原文本刊更多论文

抗体对mRNA - cov -2疫苗应答的心理相关因素：一项前瞻性观察队列研究

疫苗从根本上改变了COVID-19大流行的进程，挽救了生命。一年内有1400万人死亡。然而，疫苗赋予的保护表现出个体间的差异，许多已确定的保护相关因素（如年龄）无法改变。这项前瞻性观察队列研究考察了可改变的心理因素（抑郁症状、焦虑、感知压力和积极情绪）是否也会影响COVID-19疫苗的有效性，这些因素可以预测对其他疫苗的抗体反应。我们将重点放在新型mRNA疫苗上，因为这些疫苗具有更大的临床保护作用，并且以前没有在这些疫苗中研究过心理相关因素。方法384名成年人在英国某大规模疫苗接种中心接受了2剂BNT162b2 mRNA SARS-CoV-2疫苗疗程，完成了有效的心理测量，并在接种前和第二次疫苗接种后4周提供了血液样本。结果在控制疫苗接种前抗体水平、人口统计学和临床因素的单独线性回归模型中，较高水平的抑郁症状（β = -0.15 [95% CI: - 0.30, - 0.01], p = 0.041，部分f2 = 0.009）和较低水平的积极情绪（β = 0.16 [95% CI: 0.01, 0.30], p = 0.036，部分f2 = 0.011）与疫苗接种后较低的SARS-CoV-2尖峰特异性抗体水平显著相关。在焦虑或感知压力的测量和抗体反应之间没有观察到显著的关系。结论在参加第一次COVID-19疫苗接种的社区样本中，较慢的抑郁症状水平和更大的积极情绪与mRNA SARS-CoV-2疫苗接种后较大的抗体反应相关。由于两者都是可以改变的，因此它们可以提供增强疫苗有效性的机制，特别是在疫苗失败风险较大的人群中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Brain, Behavior, and Immunity 医学-免疫学

CiteScore

29.60

自引率

2.00%

发文量

290

审稿时长

28 days

期刊介绍： Established in 1987, Brain, Behavior, and Immunity proudly serves as the official journal of the Psychoneuroimmunology Research Society (PNIRS). This pioneering journal is dedicated to publishing peer-reviewed basic, experimental, and clinical studies that explore the intricate interactions among behavioral, neural, endocrine, and immune systems in both humans and animals. As an international and interdisciplinary platform, Brain, Behavior, and Immunity focuses on original research spanning neuroscience, immunology, integrative physiology, behavioral biology, psychiatry, psychology, and clinical medicine. The journal is inclusive of research conducted at various levels, including molecular, cellular, social, and whole organism perspectives. With a commitment to efficiency, the journal facilitates online submission and review, ensuring timely publication of experimental results. Manuscripts typically undergo peer review and are returned to authors within 30 days of submission. It's worth noting that Brain, Behavior, and Immunity, published eight times a year, does not impose submission fees or page charges, fostering an open and accessible platform for scientific discourse.